Orthocell Ltd News

Orthocell Fortifies Cash Position for US Expansion With A$3.05 Million R&D Tax Refund

Leading regenerative medicine company Orthocell Ltd (ASX:OCC, OTC:ORHHF) has secured an Australian Research and Development (R&D) Tax Incentive refund amounting to A$3.05 million for the fiscal year 2022-2023.

Investing.com Apr 15 09:54

Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3%

Orthocell (ASX:OCC) secured a AU$3 million rebate from the Australian government's research and development tax incentive scheme, according to a Monday filing with the Australian Securities Exchange.

MT NewswiresApr 15 09:31

Orthocell Revenue Soars 19% to AU$1.61 Million in Q1

Orthocell (ASX:OCC) posted its quarterly report for the period ended March 31 showing revenue rose 19% to AU$1.61 million compared with a year earlier, according to a Tuesday Australian bourse filing.

MT NewswiresApr 9 10:27

Orthocell Ltd Reports Solid Revenue Growth

TipRanksApr 8 08:48

Orthocell Moves Closer to US Market Clearance and Sales | ASX:OCC, OTC:ORHHF

Proactive InvestorsMar 26 20:50

Orthocell Completes First Stage of Remplir US Market Authorization Study

Orthocell (ASX:OCC) has completed the first stage of its Remplir US market authorization study, allowing the regenerative medicine company to move forward with the remaining two stages, according to a

MT NewswiresMar 25 07:23

Orthocell Completes AU$3.5 Million Share Placement

Regenerative medicine company Orthocell (ASX:OCC) completed a strategic placement, raising AU$3.5 million. The company issued nearly 9.5 million new fully paid ordinary shares at AU$0.37 apiece in the

MT NewswiresFeb 22 10:52

Orthocell Secures A$3.5 Million in Strategic Placement to Fund Global Expansion and US Product Registration

Regenerative medicine company Orthocell Ltd (ASX:OCC, OTC:ORHHF) has secured firm commitments for a strategic placement amounting to A$3.5 million at A$0.37 per share.

Investing.com Feb 22 07:43

Orthocell Submits Regulatory Application for Remplir in Singapore

Regenerative medicine company Orthocell (ASX:OCC) said its application to market and sell its peripheral nerve repair product Remplir in Singapore has been accepted by the Health Services Authority of

MT NewswiresFeb 13 10:05

Orthocell Board Renewal to Focus on Balance Sheet and Commercialisation

Following its appointment of former Deputy Prime Minister Kim Beazley and as part of its board renewal, Orthocell Ltd (ASX:OCC, OTC:ORHHF) will say goodbye to board member Matthew Callahan, who was instrumental in the company’s early success.

Investing.com Jan 16 06:18

Orthocell (ASX:OCC) Shareholders Have Earned a 23% CAGR Over the Last Five Years

Yahoo FinanceJan 15 12:09

Orthocell Completes Chair Transition Process

Regenerative medicine company Orthocell (ASX:OCC) said founding board member and former chair, Stewart Washer, retired after almost 10 years on the board to pursue other interests. Washer completed th

MT NewswiresDec 22, 2023 10:56

Orthocell Initiated at Speculative Buy by Euroz Hartleys

Orthocell Initiated at Speculative Buy by Euroz Hartleys

Dow JonesDec 14, 2023 12:35

The Five-year Returns Have Been for Orthocell (ASX:OCC) Shareholders Despite Underlying Losses Increasing

Yahoo FinanceJul 19, 2023 05:32